Related by context. All words. (Click for frequent words.) 70 multicenter randomized placebo controlled 68 Initiated Phase 68 GetGoal Phase III 67 multicenter placebo controlled 67 BRIM2 67 multicenter randomized double 67 BRIM3 66 Bayer HealthCare Onyx Pharmaceuticals 66 placebo controlled Phase 66 randomized multicenter 66 multicentre randomized double 66 Phase Ib clinical 66 treatment naive genotype 66 evaluating tivozanib 65 blinded randomized placebo controlled 65 R#/MEM # 65 Randomized Placebo Controlled 65 azilsartan medoxomil 65 relapsed MM 65 Desvenlafaxine Succinate 65 Randomized Phase 65 CIMZIA TM certolizumab pegol 65 multicenter randomized controlled 64 Initiate Phase 64 Phase III randomized 64 evaluating mipomersen 64 Randomized Double blind 64 ascending dose 64 phase IIb clinical 64 Phase Ib IIa 64 Phase Ib II 64 Testosterone MDTS R 64 Second Pivotal Phase 64 Phase IIA 64 multicenter multinational 64 Phase 1a clinical 64 Phase IIIb 64 ALN VSP Phase 64 Multicenter Randomized Double 64 Completes Patient Enrollment 64 multicenter Phase 64 Randomized Double Blind 63 Placebo Controlled 63 Randomized Phase II 63 INCB# [001] 63 treatment naïve genotype 63 Phase III multicenter 63 double blinded randomized 63 Pivotal Phase III 63 Demonstrates Positive 63 Recurrent Glioblastoma 63 eosinophilic asthma 63 phase Ib 63 Meets Primary Endpoint 63 randomized controlled multicenter 63 initiated Phase Ib 63 phase IIa clinical 63 Study Evaluating 63 desvenlafaxine succinate 63 forodesine 63 Phase III placebo controlled 63 Phase IIIb clinical 63 Phase Ia 63 number NCT# ClinicalTrials.gov 63 REVIVE Diabetes 63 dose escalation phase 63 CHAMPION PCI 63 placebo controlled randomized 63 comparing XIENCE V 62 ENESTnd 62 prospective randomized placebo 62 phase IIb study 62 Pivotal Phase 62 blinded placebo controlled 62 Dose Escalation 62 Oral Fingolimod 62 IMPACT DCM 62 Folfox 62 registrational Phase 62 OPT CHF 62 Proellex TM 62 Testosterone MDTS ® 62 Adjunctive Therapy 62 multicenter Phase III 62 Phase III Pivotal 62 masked placebo controlled 62 CATIE AD 62 AVOREN 62 BR.# 62 thorough QT 62 Androxal TM 62 Matrix Phase 2b 62 double blinded placebo 62 prospective multicentre 62 multicenter randomized 62 multicentre randomized 62 recombinant PSMA vaccine 62 ORENCIA ® 62 Vicriviroc 62 NOXAFIL Oral Suspension 62 Phase 2a clinical 62 albiglutide 62 receiving INTRON 62 Phase 1b clinical 62 HCV RESPOND 2 62 placebo controlled dose escalation 62 midstage clinical 62 Initiates Phase II 62 Relapsing Multiple Sclerosis 62 Phase IIB 62 multicenter Phase II 62 placebo controlled Phase III 62 Initiates Phase III 62 dose escalation Phase 62 controlled multicenter 61 RECORD1 61 Phase #/#a 61 dose escalation trial 61 randomized placebo controlled 61 Phase III Clinical Trial 61 recurrent glioblastoma multiforme 61 Randomized Controlled 61 Decompensated Heart Failure 61 AIR CF1 61 Pivotal Trial 61 phase IIa 61 investigational protease inhibitor 61 INSPIRE Trial Phase III 61 Acute Decompensated Heart Failure 61 ROCKET AF 61 Phase 2b Clinical Trial 61 heFH 61 placebo controlled 61 Prospective Randomized 61 Relapsed Multiple Myeloma 61 Trial Evaluating 61 REVIVE TA 61 ENDEAVOR IV 61 dose escalation clinical 61 XL# SAR# 61 APEX PD 61 phase IIIb 61 By JENNIFER LEARN 61 novel histone deacetylase 61 Urocortin 2 61 Naive Patients 61 ID NCT# 61 ExTRACT TIMI 61 LAB CGRP 61 Initiates Enrollment 61 label multicenter randomized 61 Achieves Primary Endpoint 61 single ascending dose 61 prospective nonrandomized 61 evaluable subjects 61 dosing cohort 61 ADVANCE PD 61 EXPLORE Xa 61 Randomised 61 Successfully Completes Phase 61 CLARITY study 61 Placebo controlled 61 ORACLE MS 61 oxycodone CR 61 HCV SPRINT 61 Combination REOLYSIN R 61 retinal vein occlusion induced 61 telaprevir dosing 61 aflibercept VEGF Trap 61 Phase 2b Study 61 phase IIb 61 galiximab 61 IIa trial 60 Elagolix 60 placebo controlled clinical 60 keloid scarring 60 Multiple Ascending Dose 60 CIMZIA TM 60 Mg Usa 60 Zemplar Capsules 60 blind multicenter 60 Severe Sepsis 60 GOUT 60 confirmatory clinical 60 de novo kidney transplant 60 TELINTRA R 60 mg q#h 60 Multicenter Phase 60 Phase IIb Trial 60 Treatment Experienced 60 multicenter dose escalation 60 First Patient Enrolled 60 Multicenter 60 FOLFOX6 chemotherapy regimen 60 blind placebo 60 Protease Inhibitor 60 Follicular Lymphoma 60 acyclovir Lauriad R 60 CYT# potent vascular disrupting 60 generation PNP inhibitor 60 Ophena TM 60 Heterozygous Familial Hypercholesterolemia 60 See CLINICAL PHARMACOLOGY 60 symptomatic BPH 60 AEGR 60 Sapacitabine 60 humanized interleukin 6 60 Betaferon R 60 PF # [002] 60 omacetaxine mepesuccinate 60 controlled multicenter Phase 60 randomized Phase IIb 60 primary hypercholesterolemia 60 3 registrational trial 60 AIR CF2 60 ACTEMRA TM 60 Randomized controlled 60 Systemic Sclerosis 60 multiple ascending dose 60 EOquin TM phase 60 MEND CABG 60 IMPACT DCM clinical 60 Advanced Melanoma 60 Sorafenib HCC Assessment 60 Completes Enrollment 60 prospective randomized multicenter 60 Omacetaxine 60 Clinical Trial Evaluating 60 Zenvia ™ 60 randomized #:#:# 60 ongoing Phase 1b 60 TAXUS ATLAS 60 Intervention Effectiveness 60 Phase #b/#a trial 60 fostamatinib 60 LUX Lung 60 opioid naive 60 PROTECT AF 60 assessing T DM1 60 Phase 1a 60 Carotid Revascularization Endarterectomy vs. 60 Phase Ib Clinical Trial 60 delivers fluocinolone acetonide FA 60 NSABP B 60 Hypoactive Sexual Desire Disorder 60 NCT# ClinicalTrials.gov 60 randomized multicenter trial 60 Phase IIa Clinical Trial 60 CALGB # [002] 60 phase Ib clinical 60 Phase IIIb study 60 Pooled Analysis 60 prospective multicenter 60 pramlintide metreleptin 60 ABSORB clinical 60 Phase 1b dose escalation 60 infliximab monotherapy 60 intravenous RSD# 60 Investigational Treatment 60 CCR5 mAb 59 certolizumab 59 dosing cohorts 59 ADMIRE HF 59 ORENCIA R 59 GATTEX ® 59 Aflibercept 59 Ozarelix 59 chemotherapy FOLFOX 59 Triapine 59 MERLIN TIMI 59 Clinical Antipsychotic Trials 59 8mg/kg 59 Confirmatory Phase 59 Cutaneous T 59 CEL SCI Phase III 59 Initiates Clinical Trial 59 Luramist TM 59 LUMINATE 59 KRN# 59 metastatic GIST 59 Prolongs Survival 59 colesevelam HCl 59 systemic Phase 1b 59 TASKi2 59 Refractory Hodgkin Lymphoma 59 PI3K/Akt pathway inhibitor 59 PD LID 59 bone marrow reticulin deposition 59 Initiates Clinical 59 tenofovir emtricitabine 59 Dupuytren Disease 59 evaluating satraplatin 59 prospective multicenter randomized 59 refractory chronic lymphocytic 59 GATTEX ™ 59 biliary tract cancer 59 controlled dose escalation 59 novel oral anticoagulant 59 Glufosfamide 59 primary generalized tonic 59 Early Relapsing Multiple 59 SPRYCEL ® 59 oral deforolimus 59 selective phosphodiesterase 59 approved incretin mimetic 59 Acute Ischemic Stroke 59 opioid induced bowel dysfunction 59 MoxDuo TM IR 59 TMC# C# 59 PRE SURGE 59 venlafaxine XR 59 Parathyroid Hormone 59 Anturol TM 59 Phase Ib 59 dimebon latrepirdine 59 tramiprosate Alzhemed TM 59 Metastatic Prostate Cancer 59 RSD# oral 59 RELOVAIR ™ 59 TRANSFORMS 59 serotonin norepinephrine reuptake inhibitor 59 rALLy clinical trial 59 Novel Oral 59 Efficacy Results 59 multicentre prospective 59 TASKi3 59 Phase #b/#a clinical 59 Phase 2b randomized 59 Major Depressive Disorder MDD 59 pharmacogenomic translational research 59 Brentuximab Vedotin SGN 59 novel orally inhaled 59 CIMZIA ™ 59 landmark ATHENA 59 multicenter prospective 59 metastatic malignant 59 #mg BID [001] 59 recurrent malignant glioma 59 Telik logo TELINTRA 59 imetelstat GRN#L 59 unfractionated heparin UFH 59 Double Blind Placebo 59 LEVAQUIN ® 59 BLOOM Behavioral modification 59 IL# PE#QQR 59 huN# DM1 59 APTIVUS r 59 Intravitreal 59 SPIRIT FIRST 59 ORAL Solo 59 LibiGel Phase III 59 STRIDE PD 59 cathepsin K inhibitor 59 severe oral mucositis 59 acetonide FA 59 AN# topical anti 59 icatibant 59 Fx #A 59 Myelodysplastic Syndrome MDS 59 neovascular form 59 pegylated interferon alpha 59 Clinical Trials Update 59 mGluR2 positive 59 PSMA ADC 58 Forodesine HCl 58 RhuDex 58 GENASIS clinical 58 Hedgehog Pathway Inhibitor 58 PREZISTA r 58 Vascugel ® 58 randomized double 58 non nucleoside inhibitor 58 rasagiline tablets 58 Phase 1b 58 Phase IIa trials 58 BCIRG 58 Phase 1b trial 58 PRECiSE 58 Begins Dosing 58 ABSORB trial 58 Demonstrates Sustained 58 adjunctive ABILIFY 58 TKB# 58 Phase 2b study 58 TM pralatrexate injection 58 DEB# 58 inflammatory PDE 58 IIb clinical trial 58 label multicenter 58 Mg Uk 58 Phase #b/#a 58 Kinesin Spindle Protein KSP 58 huC# DM4 58 Prodarsan R 58 lead Aganocide compound 58 Adjuvant Treatment 58 Cloretazine 58 CIMZIA R 58 REG2 58 PORxin TM platforms 58 Improves Outcomes 58 Vitrasert R 58 Investigational Oral 58 ORAL Sync 58 induced macular edema 58 ToGA 58 adjunctive placebo 58 subcutaneous methylnaltrexone 58 Tarceva TM 58 Phase Ib study 58 Malignant Glioma 58 Single Dose 58 evaluating Actimmune 58 Neovascular Age Related Macular 58 bevirimat Study 58 MGd 58 PCI ExTRACT TIMI 58 Long Term Efficacy 58 cobiprostone 58 MOTIVATE 58 Phase IIIB IV 58 Crofelemer budesonide foam 58 Romidepsin 58 GAMMAGARD 58 oral rivaroxaban 58 Oral NKTR 58 Phase IIa clinical 58 Phase III randomized controlled 58 acute mania 58 pivotal bioequivalence 58 Phase 1b clinical trials 58 dependent kinase inhibitor 58 metaglidasen 58 Prostate AdenoCarcinoma Treatment 58 MIST II 58 mg administered orally 58 dose cohort 58 Phase 2a Clinical Trial 58 FDA APPROVES 58 Empatic ™ 58 MADIT II 58 oral methylnaltrexone 58 initiate Phase IIa 58 diabetic neuropathic pain 58 Phase 2a trial 58 CERVARIX 58 recurrent glioma 58 MAGE A3 ASCI 58 Phase 2a 58 GSK# [001] 58 budesonide foam 58 PDX pralatrexate 58 PRoFESS 58 ALISTA TM 58 N#HSWD 58 Patients Treated With 58 Syncria albiglutide 58 TLK# 58 kidney urologic 58 dextromethorphan quinidine 58 Treatment Naive Patients 58 Glatiramer Acetate 58 randomized controlled Phase 58 ADVANCE ILLUMINATE 58 CombAT 58 PLX STROKE targeting 58 EVIZON TM 58 brivanib 58 Phase III Trial 58 Trandolapril 58 Sprycel dasatinib 58 Active Ulcerative Colitis 58 Platelet Inhibition 58 microgram kg 58 Presents Preclinical 58 placebo controlled multicenter 58 label dose titration 58 PreCISe 58 oral sapacitabine 58 ZACTIMA 58 humanized therapeutic 58 sequential dose escalation 58 fosbretabulin 58 mecarbil 58 lintuzumab SGN 58 Efficacy Trial 58 Commences Phase 58 dyskinesia PD LID 58 Peginterferon 58 pharmacokinetic PK study 58 ® natalizumab 58 Pivotal Clinical Trial 58 Clinical Trial Results 58 NATRECOR R 58 Relapsing Remitting Multiple Sclerosis 58 LymphoStat B TM 58 Aggressive Reduction 58 randomized Phase 2b 58 Fibrillex TM 58 INS# [001] 58 interferon gamma 1b 58 EDEMA3 58 Hepatocellular Carcinoma HCC 58 II Clinical Trial 58 Elotuzumab 58 Submits Biologics License Application 58 Cholesterol Levels SPARCL 58 TRA 2P 58 Pegylated Liposomal Doxorubicin 58 #mg/day [001] 58 Initiates Phase 58 ritonavir boosted atazanavir 58 AA Amyloidosis 58 neutropenic sepsis 58 intravesical infusion therapy 58 Contrave# 58 Wisconsin Sleep Cohort 58 R lenalidomide 58 Fast Tracked Phase 58 Phase III metastatic melanoma 58 Diabetic Macular Edema 58 Phase 2a clinical trials 58 trial evaluating Prochymal 58 resectable pancreatic cancer 58 APTIVUS 58 sapacitabine CYC# 58 bicifadine 58 dose escalation study 58 antiretroviral naive 58 adalimumab Humira 58 prokinetic agent 58 multicentre randomized controlled 58 plus dexamethasone 58 randomized controlled 58 NDA Submission 58 Pre RELAX AHF 58 plus methotrexate 58 Perifosine KRX 58 RE LY ® 58 Randomized Evaluation 58 NO# [002] 58 virus HCV protease inhibitor 58 Pharmacokinetics PK 58 NCT# 57 catheter occlusion 57 Multicenter Randomized 57 mcg linaclotide 57 MIVI III 57 Hormone Refractory Prostate Cancer 57 zoledronic acid Reclast 57 active comparator 57 Phase III confirmatory 57 TBC# 57 Newly Diagnosed Multiple Myeloma 57 Presents Positive 57 naïve HCV 57 clinical trials Archexin 57 myocardial infarction ventricular fibrillation 57 evaluating Xcytrin 57 divalproex sodium 57 Quinamed 57 advanced medullary thyroid 57 IMPDH inhibitor 57 Adenoma Prevention 57 evaluating Vectibix 57 moderate hepatic impairment 57 FOLOTYN ® 57 vaccinated PNH patients 57 multicenter 57 Topline Results 57 RLAI 57 Combination Treatment 57 DASISION 57 bortezomib Velcade R 57 recurrent metastatic ovarian cancer 57 mg QD 57 HCD# [002] 57 including eniluracil ADH 57 multicenter clinical 57 Pegasys plus Copegus 57 Xeloda ® 57 Diabetic Foot Ulcer 57 Pivotal Study 57 plus prednisone prednisolone 57 Lupus Drug 57 cisplatin gemcitabine 57 TO AVOID PREGNANCY WHILE 57 Initiate Phase III 57 Cloretazine R VNP#M 57 CTA# Injection 57 mertansine 57 lexidronam injection 57 Phase II 57 virologically suppressed 57 Randomized Phase III 57 BCR ABL inhibitor 57 randomized crossover 57 non splenectomized 57 iniparib BSI 57 XL# anticancer compounds 57 Neulasta R 57 docetaxel Taxotere R 57 rALLy 57 OAB overactive bladder 57 YONDELIS 57 daily subcutaneous injections 57 CONQUER OB 57 Randomized Clinical Trial 57 VIVITROL ® 57 Pulmonary Arterial Hypertension 57 MEVACOR 57 TDF FTC 57 PhG alpha 1 57 biologic DMARD 57 markets Testim ® 57 Inc. Nasdaq ALSE 57 Cannabinor 57 LUNESTA TM 57 Silodosin 57 evaluating carfilzomib 57 Neovascular AMD 57 decompensated liver disease 57 evaluating tesamorelin 57 SCH # 57 Cimzia ® certolizumab pegol 57 Phase III Clinical Trials 57 NOX E# 57 PANVAC VF 57 Phase IIb randomized 57 HuMax EGFr 57 evaluating T DM1 57 CALERIE 57 somatostatin analog 57 randomized blinded 57 Velcade bortezomib 57 Submits NDA 57 selective androgen receptor modulator 57 Phase 2b clinical 57 multicenter randomized clinical 57 Dose Ranging 57 memantine HCl 57 lenalidomide Revlimid R 57 antiretroviral naïve 57 Initiate Phase II 57 Degarelix 57 mitoxantrone plus 57 Edge STudy 57 Patient Enrolment 57 partial onset seizures 57 Nasdaq PGNX today 57 CYP#A# CYP#D# 57 Scandinavian Simvastatin Survival 57 non nucleoside HCV 57 IIa clinical 57 teriflunomide 57 nucleotide analog 57 Non Alcoholic Steatohepatitis 57 bepotastine besilate nasal spray 57 Phase 2b trial 57 malignant mesothelioma Alfacell 57 label dose escalation 57 alvespimycin 57 ongoing Phase IIIb 57 PREZISTA ritonavir 57 CAMMS# 57 lumiliximab 57 ANCHOR trial 57 Custirsen 57 sodium thiosulfate STS 57 cancer neuroendocrine tumor 57 brivaracetam 57 Relapsed Refractory 57 multicenter phase 57 Phase 2b kidney transplant 57 multicenter randomized Phase 57 LEVADEX ™ 57 AIR CF3 57 Aeolus Pharmaceuticals Announces 57 novel VDA molecule 57 COU AA 57 ACTIVE W 57 achieved ACR# 57 Phase III 57 aplindore 57 JAK2 Inhibitor 57 antibody MAb 57 Phase III Psoriasis 57 Linagliptin 57 alfa 2a 57 MEK Inhibitor 57 oral ridaforolimus 57 Safinamide 57 Blind Placebo Controlled Trial 57 Gemzar ® 57 Hsp# Inhibitor 57 Current Controlled Trials 57 ug dose 57 QLT# 57 crizotinib PF # 57 Prospective Multicenter 57 OMP #R# 57 Screening Trial 57 Clinicaltrials.gov 57 Vitaxin 57 elagolix 57 AIM HIGH 57 MoxDuo IR 57 ancrod 57 Toremifene 57 HCV NS5B polymerase 57 designated HVTN 57 Preclinical Models 57 EchoCRT 57 Renal Impairment 57 Presents Positive Preclinical 57 Phenoptin 57 GRN# 57 Pemetrexed 57 Val HeFT 57 phase IIb III 57 Demonstrates Significant 57 confirmatory Phase III 57 HIV HCV coinfected 57 Fabry Disease 57 myelodysplastic myeloproliferative diseases 57 ascending dose study 57 Refractory Angina 57 Dose escalation 57 Patient Enrollment 57 Peginterferon Alfa 2a 57 REALITY Trial 57 Vascular Disrupting Agent 57 Phase IIb Clinical Trial 57 sorafenib tablets 57 MADIT 57 unique alkylating agent 57 intravitreal insert 57 Phase 2b Trial 57 Antitumor Activity 57 PARGLUVA 57 tapentadol ER 57 atazanavir ritonavir 57 initiate multicenter 57 Shows Promising 57 Phase 2a Trial 57 TG MV 57 Aryplase 57 HeFH 57 Simulect 57 CRLX# 57 alemtuzumab Campath 57 Glycopyrrolate 57 Cell Lymphoma 57 Engerix B 57 enoximone capsules 57 zonisamide SR 57 ALN HPN 57 riociguat 57 PEG INTRON R 57 #mg #mg #mg [003] 56 Adalimumab 56 generation DACH Platinum 56 SUCCEED trial 56 complement inhibitor eculizumab 56 blinded randomized 56 orally inhaled migraine 56 HORIZONS AMI 56 PRTX 56 Callisto initiated 56 Teriflunomide 56 Rigel R# 56 inhalations twice 56 miconazole Lauriad ® 56 randomized multicentre 56 Pegasys ® 56 Hepatotoxicity 56 patients evaluable 56 Phase 1b Clinical Trial 56 relapsing multiple sclerosis 56 brand ciclesonide HFA 56 plus gemcitabine 56 LymphoStat B Phase 56 EMPHASIS HF trial 56 aripiprazole Abilify 56 Shows Efficacy 56 hoFH 56 phase 2a 56 Plaque Psoriasis 56 JZP 56 DU #b 56 Antiviral Activity 56 oral prodrug 56 PROSTVAC VF 56 RE SURGE 56 PERSEUS clinical program 56 Raptiva r 56 yearly subcutaneous injections 56 baminercept 56 Controlled Trial 56 KNS # 56 REG1 Anticoagulation System 56 pralatrexate injection folate analogue 56 pharmacokinetics PK 56 CAPACITY trials 56 EURIDIS 56 IV RSD# 56 Atrasentan 56 occlusion PAO 56 Primary endpoints 56 Phase 2b clinical trials 56 Enzastaurin 56 Investigator Initiated 56 Therapy Evaluation 56 sorafenib Nexavar ® 56 CB2 selective receptor agonist 56 azathioprine monotherapy 56 phase IIb trial 56 REGN# 56 Dacogen injection 56 telomerase inhibitor drug 56 GATTEX TM 56 TYGACIL 56 leukemia AML 56 prospective multicenter study 56 oral levofloxacin 56 PEGINTRON TM 56 metastatic renal cell 56 Multicenter Automatic Defibrillator Implantation 56 Pivotal Trials 56 Chronic Myeloid Leukemia 56 VICTOR E3 56 ThermoDox R 56 pioglitazone hydrochloride 56 Pharmacodynamic 56 XIENCE V Stent System 56 mg BID dose 56 Paxil paroxetine 56 mcg kg REBETOL 56 Unstable Angina 56 Traficet EN 56 interferon beta 1b 56 MIRAPEX ER 56 Targretin capsules 56 either acutely decompensated 56 FOLFIRI chemotherapy 56 YOUR LOCAL ANIMAL SHELTER 56 pan histone deacetylase 56 Dose Ranging Study 56 PrevOnco 56 VEGFR2 inhibitor 56 TTF Therapy 56 Anthrax Toxin 56 mg BID 56 HIV uninfected 56 novel tubulin binding 56 ibandronate 56 Preclinical Study 56 Sipuleucel T 56 phase III isavuconazole 56 highly purified pasteurized 56 personalized cellular immunotherapy 56 MEND CABG II 56 HCV Genotype 56 unresectable Stage III 56 octreotide LAR 56 relapsed refractory AML 56 prospective observational cohort 56 placebo dexamethasone 56 ENDEAVOR III 56 clozapine Clozaril 56 IMPACT DCM trial 56 undergoing elective percutaneous 56 Medidur TM FA 56 Sanofi Pasteur Fluzone 56 hyperphenylalaninemia HPA due 56 MKC# MT 56 RANK Ligand inhibitor 56 venlafaxine ER 56 diagnosed Ph + 56 Ixempra 56 RE MODEL 56 retrospective observational study 56 #mg QD [002] 56 SinuNase ™ 56 PET FROM 56 rhIGF-I/rhIGFBP-3 56 acute PAO 56 Telithromycin 56 rufinamide 56 TRANSDUR ™ 56 comparator arm 56 relapsed refractory multiple myeloma 56 CML CP 56 Serious adverse reactions 56 pain palliation 56 IND Filing 56 SIMPADICO 56 Talotrexin 56 TAXOTERE R 56 AIR2 Trial 56 relapsed myeloma 56 Alzhemed TM 56 HDAC Inhibitor 56 EXPAREL TM 56 CLL SLL 56 comparing alemtuzumab 56 Lung Cancer Trial 56 observer blinded randomized 56 multinational multicenter randomized 56 Sym# 56 Levetiracetam 56 NSABP C 56 reslizumab 56 lopinavir r arm 56 cannabinor 56 Long Lesion 56 post herpetic neuralgia PHN 56 CCX# B 56 VIRAMUNE XR 56 morphometric vertebral fractures 56 via intradermal injections 56 telaprevir dosed 56 APEX AMI trial 56 Trimesta 56 Double Blind Randomized 56 ZOLINZA 56 Dabigatran etexilate 56 lomitapide 56 Patients Receiving 56 PROVENGE ® 56 HIV treatments Reyataz 56 weekly subcutaneous injections 56 trastuzumab DM1 T DM1 56 IBS C 56 Soft Tissue Sarcoma 56 quadrivalent HPV vaccine 56 older NSAID diclofenac 56 Mipomersen 56 ENL recurrence 56 acadesine 56 Left Ventricular Dysfunction 56 tipranavir r 56 Glypromate 56 Shows Promise Against 56 diarrhea predominant irritable 56 Diabetic Neuropathy 56 bazedoxifene conjugated estrogens 56 velafermin 56 IIa trials 56 See WARNINGS 56 evaluating adecatumumab 56 randomized Phase III 56 mg TID 56 Demonstrated Significant 56 ACAPODENE 56 Central Retinal Vein 56 COR Diabetes 56 ILUVIEN ® 56 GENASIS 56 ATRA IV 56 Raptiva R 56 ThermoDox ® clinical 56 Glatiramer acetate 56 Liraglutide Effect 56 Advanced Renal Cell 56 initiate Phase 1b 56 Evoltra ® 56 adjuvant GIST 56 Thorough QT 56 ritonavir boosted 56 deCODE AF TM 56 5 FU leucovorin 56 Randomized Clinical Trials 56 Daclizumab 56 Placebo Controlled Trial 56 TELCYTA 56 Oral Calcitonin 56 ziprasidone Geodon 56 LibiGel ® 56 Previously Treated 56 allosteric modulator PAM 56 Phase IIb trials 56 REYATAZ r arm 56 prednisone prednisolone plus 56 neratinib 56 MKC# 56 phase III ACCLAIM 56 Granted Orphan Drug 56 Indacaterol 56 Neo Bladder Augment 56 EINSTEIN DVT 56 Phase IIb III 56 lanthanum carbonate 56 R rilonacept Injection 56 HGS# 56 Arch Intern Med 56 intranasal formulation 56 Genasense oblimersen sodium Injection 56 ARDIS